The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Solid tumor physiology and hypoxia-induced chemo/radio-resistance: Novel strategy for cancer therapy: Nitric oxide donor as a therapeutic enhancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Cited by
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Nitric oxide release: Part II. Therapeutic applications
Carpenter, A. W., & Schoenfisch, M. H. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15273h · Cited by 964
Protein S-nitrosylation in health and disease: a current perspective
Foster, M. W., Hess, D. T., & Stamler, J. S. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.06.007 · Cited by 752
Gasotransmitters in cancer: from pathophysiology to experimental therapy
Szabo, C. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.1 · Cited by 717
Conquering the Hypoxia Limitation for Photodynamic Therapy
Wan, Y., Fu, L., Li, C., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202103978 · Cited by 705
Yang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Maeda, H., & Khatami, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0185-6 · Cited by 491
Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects
Huang, Z., Fu, J., & Zhang, Y. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01672 · Cited by 406
Maeda, H., Tsukigawa, K., & Fang, J. (2016) · Microcirculation · doi:10.1111/micc.12228 · Cited by 336
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Synthesis of Self-Assembled Porphyrin Nanoparticle Photosensitizers
Wang, D., Niu, L., Qiao, Z.-Y., Cheng, D.-B., Wang, J., Zhong, Y., Bai, F., Wang, H., & Fan, H. (2018) · ACS Nano · doi:10.1021/acsnano.8b01010 · Cited by 303
Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review
Kumari, R., Sunil, D., & Ningthoujam, R. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.041 · Cited by 263
Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy.
Ishizuka, M., Abe, F., Sano, Y., Takahashi, K., Inoue, K., Nakajima, M., Kohda, T., Komatsu, N., Ogura, S.-I., & Tanaka, T. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.11.029 · Cited by 255
Yip, D., & Cho, C. H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.008 · Cited by 236
Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
Tang, W., & Zhao, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115235 · Cited by 50
Metadata
- Authors
- Yasuda, H.
- Venue
- Nitric Oxide
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 19
- Issue
- 2
- Pages
- 205-216
- ISSN
- 1089-8603 (ISSN-L)
- OpenAlex
- W1980640822
- Cited by
- 198
- References
- 30
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.